^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

POLR2L expression

i
Other names: POLR2L, RNA Polymerase II, I And III Subunit L, RPB7.6, RPB10beta, HRPB7.6, RPABC5, RBP10, DNA-Directed RNA Polymerases I, II, And III Subunit RPABC5, Polymerase (RNA) II (DNA Directed) Polypeptide L, 7.6kDa, RNA Polymerases I, II, And III Subunit ABC5, DNA-Directed RNA Polymerase III Subunit L, RNA Polymerase II 7.6 KDa Subunit, RNA Polymerase II Subunit L, RPB10 Homolog, HsRPB10b, Polymerase (RNA) II Subunit L, RPB10
Entrez ID:
over2years
Pan-cancer integrated bioinformatic analysis of RNA polymerase subunits reveal RNA Pol I member CD3EAP regulates cell growth by modulating autophagy. (PubMed, Cell Cycle)
Taken together, we have shown the genetic and epigenetic regulation of RNAPS genes in most common tumors. We have also demonstrated the cancer-specific function of CD3EAP and POLR2D genes.
Journal • BRCA Biomarker • Pan tumor
|
BRCA (Breast cancer early onset) • POLR2L (RNA Polymerase II, I And III Subunit L) • POLR1G (RNA Polymerase I Subunit G)
|
POLR2L expression
over3years
Prognostic Role of DNA Damage Response Genes Mutations and their Association With the Sensitivity of Olaparib in Prostate Cancer Patients. (PubMed, Cancer Control)
These results demonstrate that mutation in any DDR pathway results in a poor prognosis for PCa patients. Furthermore, mutations in ATR, BLM, and MLH1 or the expression of POLR2L, PMS1, FANCE, and other genes significantly influence Olaparib sensitivity, which may be underlying therapeutic targets in the future.
Journal • BRCA Biomarker • PARP Biomarker
|
BRCA2 (Breast cancer 2, early onset) • MLH1 (MutL homolog 1) • ATR (Ataxia telangiectasia and Rad3-related protein) • PMS1 (PMS1 protein homolog 1) • FANCE (FA Complementation Group E) • POLR2L (RNA Polymerase II, I And III Subunit L)
|
BLM mutation • PMS1 mutation • POLR2L expression
|
Lynparza (olaparib)